Aging is sped up in breast cancer survivors who underwent adjuvant chemotherapy

Adjuvant chemotherapy for breast cancer is gerontogenic, defined as accelerating the pace of physiologic aging, a new study reported.

Loss of organ function, characterized by an increase in cellular senescence, is one physiological part of aging. Markers of cellular senescence have been identified as leukocyte telomere length, expression of senescence-associated cytokines including interleukin-6, and expression of p16INK4a, and ARF in peripheral blood T lymphocytes (PBTLs).

The authors previously showed p16INK4a is a marker of accelerated molecular age in PBTLs associated with smoking, physical inactivity, and chronic human immunodeficiency virus infection. To date, reports have not explored how long-term effect of cytotoxic chemotherapy given with curative intent affects molecular aging.

Hanna K. Sanoff, MD, Norman E. Sharpless, MD, and Hyman B. Muss, MD, of the Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and their colleagues prospectively collected blood and clinical data from 33 women with stage I-III breast cancer before, immediately after, 3 months after, and 12 months after anthracycline-based chemotherapy. Blood was analyzed for markers of cellular senescence.

They observed increased expression of the senescence markers p16INK4a and ARF in PBLTs immediately after chemotherapy, and these remained elevated for at least 1 year after treatment. In an independent cohort of 176 breast cancer survivors, prior chemotherapy was associated with a persistent increase in p16INK4a at an average of 3.4 years after treatment. These results suggest the age-promoting effects of chemotherapy last for several years after treatment and may be permanent.

The authors concluded, "We have shown that cytotoxic chemotherapy potently induces the expression of markers of cellular senescence in the hematologic compartment in vivo, comparable with the effects of 10 to 15 years of chronologic aging in independent cohorts of healthy donors." Further studies are underway.

Their work was published in the Journal of the National Cancer Institute (2014; doi:10.1093/jnci/dju057).

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs